chronic
obstruct
pulmonari
diseas
copd
inflammatori
airway
disord
acut
exacerb
repres
major
complic
acut
exacerb
substanti
caus
morbid
mortal
prevent
exacerb
remain
major
unmet
need
increas
interest
recent
identifi
subgroup
patient
copd
risk
exacerb
defin
frequent
exacerb
phenotyp
patient
frequent
exacerb
wors
clinic
outcom
includ
increas
morbid
acceler
lung
function
declin
greater
mortal
suggest
group
requir
special
consider
date
underli
mechan
predispos
patient
frequent
exacerb
elucid
plausibl
abnorm
host
immun
could
underli
increas
propens
exacerb
virus
major
etiolog
trigger
exacerb
data
exist
suggest
copd
may
associ
defici
antivir
immun
howev
studi
shown
abnorm
suggest
may
vari
accord
diseas
phenotyp
frequent
exacerb
could
repres
one
subgroup
defect
antivir
immun
promin
experiment
natur
occur
exacerb
studi
also
confirm
initi
viru
infect
precipit
secondari
bacteri
infect
copd
although
bacteri
colon
stabl
state
shown
associ
increas
exacerb
frequenc
propens
develop
secondari
bacteri
infect
viru
infect
frequent
versu
infrequ
exacerb
previous
studi
use
analysi
sputum
sampl
cohort
patient
monitor
prospect
commun
combin
vitro
experi
bronchial
epitheli
cell
bec
sampl
patient
copd
differenti
interfac
ali
show
innat
antivir
immun
impair
frequent
exacerb
mechan
may
underli
increas
propens
exacerb
observ
patient
cohort
copd
subject
recruit
longitudin
studi
carri
st
mari
hospit
london
uk
june
decemb
investig
pathogenesi
natur
occur
copd
exacerb
studi
protocol
approv
east
london
research
ethic
committe
studi
number
subject
gave
inform
written
consent
subject
clinic
diagnosi
copd
confirm
spirometri
subject
initi
visit
baselin
clinic
stabl
infectionfre
without
antibiot
treatment
treatment
oral
corticosteroid
least
wk
clinic
assess
spirometri
forc
expiratori
volum
forc
vital
capac
fvc
peak
expiratori
flow
pef
clinic
sampl
collect
includ
spontan
induc
sputum
taken
process
previous
describ
baselin
visit
subject
ask
number
exacerb
experienc
previou
year
divid
two
group
frequent
exacerb
exacerb
preced
year
infrequ
exacerb
exacerb
previou
year
previous
describ
subject
repeat
visit
three
monthli
interv
clinic
stabl
follow
minimum
mo
subject
report
studi
team
develop
symptom
upper
respiratori
tract
infect
increas
symptom
dyspnea
cough
sputum
volum
purul
exacerb
defin
use
east
london
cohort
criteria
subject
seen
within
h
onset
symptom
collect
sampl
repeat
visit
carri
wk
initi
exacerb
visit
sampl
cohort
use
previou
studi
investig
role
airway
glucos
copd
primari
bec
obtain
bronchoscop
patient
copd
global
initi
obstruct
lung
diseas
gold
stage
ii
iii
grown
confluenc
differenti
ali
previous
describ
subject
includ
gave
written
inform
consent
studi
protocol
approv
hunter
new
england
human
research
ethic
committe
primari
cell
grown
complet
bronchial
epitheli
cell
growth
medium
begm
lonza
growth
factor
supplement
submerg
monolay
cultur
seed
cellsml
transwel
plate
confluent
infect
multipl
infect
moi
appli
apic
surfac
h
bronchial
epitheli
basal
medium
bebm
minim
follow
infect
media
replac
fresh
bebm
minim
remaind
experi
sampl
collect
h
postinfect
apic
media
remov
store
protein
express
analys
type
iii
ifn
protein
measur
use
customdesign
legendplex
kit
biolegend
measur
use
verikin
elisa
pbl
half
transwel
membran
also
care
cut
insert
collect
rlt
buffer
qiagen
contain
downstream
molecular
analys
rtquantit
pcr
remain
transwel
membran
fix
neutralbuff
formalin
h
histolog
cross
section
confirm
differenti
mesoscal
discoveri
msd
platform
maryland
usa
use
measur
inflammatori
mediat
tnf
sputum
supernat
accord
manufactur
instruct
publish
previous
protein
level
measur
use
duoset
elisa
kit
r
system
accord
manufactur
instruct
protein
level
antimicrobi
peptid
assay
use
commerci
elisa
assay
kit
previous
describ
sourc
individu
elisa
follow
elafin
r
system
lactoferrin
cambridg
bioscienc
secretori
leucocyt
proteas
inhibitor
slpi
r
system
surfact
proteind
r
system
total
rna
extract
sputum
cell
pellet
bronchial
epitheli
cell
lysat
store
rlt
buffer
rneasi
kit
qiagen
use
cdna
synthesi
omniscript
rt
kit
quantit
pcr
carri
use
previous
describ
specif
primer
probe
gene
interest
normal
rrna
reaction
analyz
use
abi
fast
realtim
pcr
system
appli
biosystem
dna
extract
total
sputum
perform
use
fastdna
spin
kit
soil
mp
biomed
santa
ana
ca
per
manufactur
instruct
beadbeat
perform
two
cycl
rpm
precelli
bertin
technolog
montignylebretonneux
franc
total
bacteri
load
measur
use
quantit
pcr
previous
describ
virus
detect
describ
previous
comparison
sputum
mrna
express
protein
concentr
frequent
infrequ
exacerb
analyz
use
mannwhitney
u
test
vitro
experi
baselin
versu
rvinduc
express
analyz
use
ratio
pair
ttest
mann
whitney
u
test
use
compar
rv
induct
mrna
protein
frequent
infrequ
exacerb
statist
perform
use
graphpad
prism
softwar
differ
consid
signific
p
use
communitybas
cohort
copd
patient
evalu
antimicrobi
immun
baselin
stablest
virusassoci
exacerb
baselin
analys
sputumsolubl
mediat
sampl
patient
avail
patient
classifi
frequent
exacerb
clinic
characterist
shown
tabl
baselin
analys
sputum
cell
mrna
interferon
ifn
interferonstimul
gene
isg
cohort
suffici
sampl
evalu
patient
classifi
frequent
exacerb
clinic
characterist
group
shown
tabl
sinc
virus
major
caus
exacerb
defici
antivir
immun
observ
studi
copd
hypothes
frequent
exacerb
would
reduc
baselin
express
antivir
immun
mediat
thu
impair
potenti
mount
protect
respons
viru
infect
examin
baselin
sputum
cell
mrna
express
type
iii
ifn
isg
patient
communitybas
copd
cohort
found
frequent
exacerb
significantli
reduc
sputum
mrna
express
differ
fig
baselin
sputum
concentr
interferoninduc
protein
fig
also
reduc
frequent
exacerb
differ
mrna
express
isg
synthetas
oa
viperin
observ
fig
differ
baselin
sputum
level
proinflammatori
cytokin
frequent
versu
infrequ
exacerb
fig
communitybas
cohort
episod
acut
exacerb
posit
viru
detect
observ
rhinoviru
n
coronaviru
n
rsv
n
influenza
n
n
occur
patient
classifi
frequent
exacerb
clinic
characterist
exacerb
patient
shown
tabl
one
patient
hospit
exacerb
episod
treat
commun
observ
frequent
exacerb
reduc
capac
mount
innat
antivir
respons
stabl
state
next
examin
sputum
cell
mrna
express
ifn
isg
subgroup
patient
develop
exacerb
associ
posit
viru
detect
frequent
exacerb
significantli
reduc
sputum
cell
express
mrna
exacerb
present
fig
sputum
mrna
express
also
significantli
reduc
exacerb
present
frequent
versu
infrequ
exacerb
differ
observ
viperin
express
fig
frequent
exacerb
also
reduc
sputum
concentr
interferoninduc
cytokin
exacerb
onset
wk
onset
fig
observ
reduc
ifn
isg
express
frequent
exacerb
vivo
sputum
sampl
taken
exacerb
next
proceed
expand
upon
find
determin
whether
epitheli
cell
patient
copd
frequent
exacerb
defici
innat
respons
rv
infect
use
bec
collect
bronchoscop
patient
copd
n
frequent
exacerb
n
infrequ
exacerb
differenti
interfac
infect
moi
demographicclin
characterist
includ
patient
shown
tabl
signific
induct
mrna
baselin
observ
frequent
infrequ
exacerb
h
postinfect
fig
rv
induct
mrna
significantli
lower
frequent
versu
infrequ
exacerb
similar
trend
p
observ
mrna
signific
differ
observ
fig
rv
induct
isg
viperin
mrna
also
significantli
lower
frequent
versu
exacerb
signific
differ
observ
pkr
fig
signific
induct
protein
baselin
also
observ
frequent
infrequ
exacerb
h
postinfect
fig
howev
signific
differ
induct
protein
rv
frequent
infrequ
exacerb
fig
similarli
signific
induct
interferoninduc
cytokin
baselin
observ
group
subject
nonsignific
trend
p
toward
lower
induct
frequent
exacerb
fig
greater
heterogen
trend
increas
viral
load
observ
bec
frequent
exacerb
fig
also
nonsignific
trend
toward
reduc
mrna
express
cytosol
viral
patternrecognit
receptor
rigi
follow
rv
infect
frequent
versu
infrequ
exacerb
suggest
decreas
antivir
immun
respons
observ
individu
could
consequ
decreas
recognit
viral
invas
fig
evid
suggest
barrier
function
involv
differ
transepitheli
electr
resist
teer
cell
baselin
frequent
exacerb
versu
infrequ
exacerb
fig
collect
data
support
vivo
find
exacerb
patient
antivir
respons
inconsist
reduc
frequent
exacerb
extend
observ
identifi
dysregul
innat
immun
respons
bec
defin
impair
express
ifn
isg
previou
vivo
studi
report
subject
frequent
exacerb
higher
sputum
level
proinflammatori
cytokin
stabl
state
observ
airway
epitheli
cell
frequent
exacerb
impair
antivir
immun
respons
infect
next
sought
investig
whether
may
relat
greater
baselin
epitheli
product
inflammatori
cytokin
also
exist
evid
vitro
respons
bacteri
infect
may
dampen
bec
frequent
exacerb
show
nonsignific
trend
toward
increas
p
express
p
baselin
differ
observ
fig
differ
level
induct
cytokin
rv
fig
virusinduc
exacerb
trigger
subsequ
bacteri
infect
copd
secondari
phenomenon
associ
sever
rv
infect
invers
relat
interferon
respons
given
observ
defici
interferon
respons
frequent
exacerb
vitro
vivo
hypothes
phenotyp
would
associ
increas
secondari
bacteri
infect
exacerb
copd
patient
investig
measur
sputum
bacteri
load
quantit
pcr
subject
copd
stabl
state
virusassoci
exacerb
differ
sputum
bacteri
load
frequent
infrequ
exacerb
baselin
exacerb
onset
fig
b
howev
frequent
exacerb
signific
increas
log
bacteri
load
wk
exacerb
onset
fig
indic
copd
subgroup
may
increas
likelihood
secondari
bacteri
infect
virusinduc
exacerb
suggest
may
relat
defici
antivir
immun
respons
exacerb
previous
report
rhinovirusinduc
secondari
bacteri
infect
may
occur
neutrophil
elastasemedi
cleavag
reduct
antimicrobi
peptid
amp
slpi
elafin
process
occur
copd
healthi
subject
may
accentu
inhal
corticosteroid
use
given
observ
increas
bacteri
load
frequent
exacerb
next
examin
whether
subgroup
copd
patient
concurr
reduc
amp
level
differ
sputum
slpi
elafin
lactoferrin
surfactantprotein
level
frequent
infrequ
exacerb
either
baselin
fig
exacerb
fig
suggest
differenti
express
amp
underli
increas
secondari
bacteri
infect
frequent
exacerb
underli
mechan
involv
increas
suscept
frequent
exacerb
remain
crucial
research
question
copd
show
first
time
patient
copd
histori
frequent
exacerb
reduc
airway
antimicrobi
immun
assess
clinic
stabil
subsequ
virusassoci
exacerb
associ
increas
bacteri
load
addit
confirm
copd
frequent
exacerb
reduc
ex
vivo
immun
respons
rv
infect
primari
airway
epitheli
cell
indic
innat
antivir
defici
data
provid
import
mechanist
advanc
understand
clinic
import
copd
subgroup
abnorm
could
predispos
patient
greater
risk
acquisit
pathogen
virus
bacteria
andor
promot
greater
likelihood
develop
exacerb
follow
infect
previou
studi
shown
ex
vivo
type
ifn
respons
rv
infect
bronchoalveolar
cell
influenza
infect
bec
impair
copd
patient
copd
also
increas
viru
load
enhanc
exacerb
sever
experiment
infect
rhinoviru
howev
defect
antivir
immun
shown
univers
studi
report
opposit
effect
augment
ex
vivo
antivir
respons
copd
discrep
copd
studi
suggest
defect
immun
may
present
patient
number
confound
compet
factor
diseas
sever
medic
like
influenc
plausibl
patient
frequent
exacerb
might
repres
one
subgroup
impair
antivir
immun
report
express
type
type
iii
ifn
mrna
reduc
frequent
exacerb
stabl
state
suggest
patient
might
reduc
potenti
gener
protect
respons
viru
infect
support
hypothesi
also
observ
antivir
respons
includ
isg
suppress
exacerb
frequent
exacerb
rv
induct
viperin
mrna
bec
ex
vivo
also
reduc
frequent
exacerb
studi
provid
first
evid
copd
frequent
exacerb
innat
antivir
immun
dysfunct
suggest
reduct
interferon
product
might
underli
augment
propens
viru
infect
thu
increas
exacerb
frequenc
observ
patient
mechan
support
clinic
studi
report
copd
patient
frequent
exacerb
experi
significantli
coryz
episod
infrequ
exacerb
given
inhal
therapi
shown
confer
clinic
benefit
subgroup
sever
asthmat
patient
develop
cold
data
suggest
innat
immuneboost
therapi
could
effect
use
target
manner
patient
copd
evid
frequent
exacerb
less
effect
innat
immun
respons
although
observ
impair
ex
vivo
rv
induct
ifn
isg
mrna
frequent
exacerb
bec
h
postinfect
observ
correspond
differ
protein
product
type
iii
ifn
cell
timepoint
despit
lack
differ
absolut
level
ifn
protein
h
reduc
isg
express
observ
frequent
exacerb
support
less
effect
ifninduc
respons
subject
studi
limit
sampl
avail
allow
evalu
singl
timepoint
bacteri
infect
also
associ
exacerb
copd
increas
pcrbase
bacteri
detect
exacerb
versu
stabl
state
suggest
caus
role
addit
virusinduc
secondari
bacteri
infect
report
experiment
natur
occur
exacerb
previous
report
experiment
rv
challeng
patient
copd
associ
increas
frequenc
secondari
bacteri
infect
compar
healthi
subject
effect
relat
viru
load
extend
find
reveal
frequent
exacerb
higher
bacteri
load
wk
follow
onset
virusassoci
exacerb
suggest
subgroup
copd
patient
might
greatest
risk
develop
secondari
bacteri
infect
follow
initi
viru
infect
data
provid
justif
develop
antivir
immun
boost
therapi
approach
reduc
secondari
bacteri
infect
associ
exacerb
sever
copd
import
note
causat
infer
result
studi
although
found
reduc
antimicrobi
respons
patient
histori
frequent
exacerb
reliabl
conclud
abnorm
directli
lead
inher
increas
exacerb
risk
per
se
like
number
addit
factor
may
contribut
observ
differ
notabl
stabl
state
analys
frequent
exacerb
show
trend
toward
greater
ic
use
less
commonli
observ
gold
stage
group
confound
could
contribut
directli
indirectli
differ
observ
previous
report
therefor
consid
studi
hypothesi
gener
emphas
import
futur
larger
vivo
studi
care
dissect
influenc
variou
factor
definit
answer
question
whether
defici
antimicrobi
immun
underli
propens
exacerb
frequenc
copd
limit
studi
classif
frequent
exacerb
made
clinic
histori
taken
studi
entri
patient
ask
exacerb
histori
preced
year
exclud
recollect
event
may
inaccur
subject
unabl
corrobor
data
medic
record
due
heterogen
natur
locat
exacerb
report
manag
selfmanag
primari
care
physiciandirect
therapi
hospit
prevent
systemat
approach
data
retriev
also
import
note
rel
short
followup
period
adopt
studi
sinc
exacerb
may
influenc
season
variat
influenza
rate
longerterm
followup
period
may
offer
accur
inform
short
followup
studi
make
unsuit
test
hypothesi
whether
baselin
defici
antivir
immun
predispos
subsequ
increas
frequenc
virusinduc
exacerb
adequ
power
studi
longer
followup
would
requir
formal
test
studi
show
subject
prior
histori
frequent
exacerb
reduc
express
antivir
immun
mediat
prospect
evalu
hypothesi
studi
much
longer
followup
period
median
day
frequent
exacerb
experienc
significantli
coryz
episod
infrequ
exacerb
support
phenotyp
potenti
associ
increas
suscept
viral
infect
previou
studi
also
indic
exacerb
risk
copd
dynam
may
chang
year
year
suggest
factor
increas
clinic
attend
thu
potenti
exposur
virus
associ
prior
frequent
exacerb
may
govern
subsequ
exacerb
risk
longerterm
studi
repeat
airway
sampl
would
need
determin
whether
baselin
antimicrobi
respons
similarli
dynam
natur
identif
underli
mechan
explain
observ
impair
antivir
immun
frequent
exacerb
challeng
due
confound
factor
inhal
corticosteroid
use
make
difficult
determin
immun
abnorm
inher
due
diseas
phenotyp
previou
studi
indic
frequent
exacerb
increas
system
local
express
proinflammatori
cytokin
current
studi
show
trend
toward
increas
baselin
product
inflammatori
cytokin
hint
chronic
airway
inflamm
could
contribut
defect
antivir
respons
upon
infect
observ
patient
previou
studi
airway
epitheli
cell
cultur
demonstr
proinflammatori
cytokin
exposur
impair
epitheli
express
cathelicidin
antimicrobi
peptid
antibacteri
antivir
properti
exposur
proinflammatori
cytokin
induc
persist
epigenet
chang
modifi
innat
immun
respons
exposur
airway
epitheli
cell
donor
asthmainduc
longlast
modif
dna
methyl
previous
report
increas
rvinduc
type
ifn
express
heterozyg
mice
compar
mice
associ
lower
express
inflammatori
consist
neg
regul
ifn
signal
inflammatori
pathway
studi
need
investig
whether
proinflammatori
cytokin
similarli
impair
interferon
express
copd
mechan
underli
effect
conclus
show
patient
copd
histori
frequent
exacerb
reduc
antivir
immun
associ
increas
secondari
bacteri
infect
immun
defect
may
underli
increas
propens
exacerb
observ
subgroup
provid
evid
support
therapeut
approach
boost
innat
immun
copd
work
support
imperi
colleg
healthcar
trust
biomed
research
centr
grant
academi
medic
scienc
wellcom
trust
starter
grant
medic
research
council
program
grant
british
medic
associ
hc
rosco
fellowship
blfseverin
wunderman
famili
foundat
lung
research
program
grant
imperi
colleg
nihr
brc
fund
scheme
nihr
clinic
lectur
fund
scheme
wellcom
trust
clinic
research
train
fellowship
british
lung
foundat
pump
prime
grant
l
johnston
person
receiv
consult
fee
myelo
therapeut
gmbh
concert
pharmaceut
bayer
sanofi
pasteur
aviragen
institut
receiv
consult
fee
synairgen
novarti
boehring
ingelheim
chiesi
glaxosmithklin
centocor
l
johnston
inventor
patent
use
inhal
interferon
treatment
exacerb
airway
diseas
none
author
conflict
interest
financi
otherwis
disclos
mc
jg
jf
pabw
clg
slj
nwb
pm
conceiv
design
research
sll
mc
ljf
mbtt
eb
jg
pv
psp
ksn
ar
jf
nwb
pm
perform
experi
sll
jg
jf
nwb
pm
analyz
data
sll
slj
nwb
interpret
result
experi
nwb
prepar
figur
draft
manuscript
sll
jg
ar
slj
nwb
pm
edit
revis
manuscript
sll
mc
ljf
mbtt
eb
jg
pv
psp
ksn
ar
slj
nwb
pm
approv
final
version
manuscript
